MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
MOTS-C Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of mitochondrial DNA, first characterized by Changhan Lee and colleagues in Cell Metabolism in 2015. It acts as a mitochondrial-nuclear signaling molecule that translocates to the nucleus under metabolic stress, regulates AMPK activation, enhances glucose uptake and insulin sensitivity, and increases fatty acid oxidation [PMID: 25738459]. In aged mice, MOTS-c administration improves glucose tolerance, increases running endurance, and partially reverses age-associated weight gain, framing it as a mitochondrial exercise-mimetic peptide. Circulating MOTS-c declines with age and with type 2 diabetes. People study it for metabolic disease, sarcopenia, longevity, and exercise capacity. MOTS-c is a research peptide with no completed human safety or efficacy trials, no IND, and is not approved for any indication; injection sourcing is grey-market.
Reconstitute: Add 2 mL bacteriostatic water → 1.67 mg/mL concentration.
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL = 0.0167 mg (17 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen at −20 °C; reconstituted refrigerated at 2–8 °C; use within 2–4 weeks[11][12].
Mitochondrial DNA-encoded: MOTS-c is one of only a handful of known mitochondrial-derived peptides (alongside humanin and SHLPs). Its mtDNA origin means natural production is sensitive to mitochondrial heteroplasmy and aging.
Rodent endurance data: Aged mice given MOTS-c intraperitoneally showed substantially increased treadmill running distance and improved grip strength versus controls, but human translation, dose scaling, and immunogenicity remain entirely uncharacterized.
WADA Prohibited List status: MOTS-c was added to the WADA Prohibited List in 2023 under S2 (peptide hormones, growth factors and related substances) because of its purported metabolic and endurance-enhancing effects.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake vigorously).
Inject slowly; wait a few seconds before withdrawing the needle to ensure complete delivery.
Do not aspirate for subcutaneous injections[7]; inject slowly and steadily over 2–5 seconds.
Interactive MOTS-C Syringe Calculator
Currently visualizing the 5 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 5mg dry powder in 2mL water yields 2.50 mg/mL. To evaluate a 250mcg dose, pull to 10.0 units (10 syringe ticks).
U-100 Syringe Representation
10.0 Units (10 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 30 units (0.30 mL) |
| Weeks 3–4 | 1000 mcg (1.0 mg) | 60 units (0.60 mL) |
| Weeks 5–6 | 1500 mcg (1.5 mg) | 90 units (0.90 mL) |
| Weeks 7–8 | 2000 mcg (2.0 mg) | 120 units (two 60‑unit injections)* |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 5 mg vial.
Peptide Vials (MOTS-C, 5 mg each):
- check8 weeks ≈ 12 vials (average ~1.1 mg/day)
- check12 weeks ≈ 18 vials
- check16 weeks ≈ 24 vials
Insulin Syringes (U‑100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- check8 weeks (12 vials): 36 mL → 4 × 10 mL bottles
- check12 weeks (18 vials): 54 mL → 6 × 10 mL bottles
- check16 weeks (24 vials): 72 mL → 8 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- check12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- check16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Mechanism of Action (MOA)
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide (MRWQEMGYIFYPRKLR) encoded within a short open reading frame in the 12S ribosomal RNA gene of the mitochondrial genome. The discovery by Lee, Cohen, and colleagues in 2015 fundamentally challenged the long-held view that all human signaling peptides are encoded by the nuclear genome, establishing MOTS-c as the founding member of a new class of mitochondrial-derived peptides (MDPs) that also includes humanin, SHLP1-6, and Gau [1]. The mature MOTS-c peptide is translated from mitochondrial DNA on mitochondrial ribosomes and exported into the cytosol, where it functions as a metabolic regulator. Mechanistically, MOTS-c acts through several interrelated pathways. First, in skeletal muscle and adipose tissue, MOTS-c activates AMP-activated protein kinase (AMPK) through inhibition of folate-mediated one-carbon metabolism, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which directly activates AMPK. Downstream AMPK activation drives the same metabolic adaptations as endurance exercise: increased glucose uptake via GLUT4 translocation, increased fatty acid oxidation, mitochondrial biogenesis, and improved insulin sensitivity [1]. Second, under metabolic stress, MOTS-c translocates from the mitochondria to the nucleus, where it acts as a transcription factor co-regulator binding antioxidant response elements (ARE) and stress-response gene promoters. Reynolds and colleagues demonstrated in a 2021 Nature Communications paper that MOTS-c expression is induced in human skeletal muscle by exercise, that circulating MOTS-c declines with age, and that intermittent late-life MOTS-c treatment in mice increases physical capacity, muscle homeostasis, and healthspan [2]. Third, MOTS-c directly binds and activates casein kinase 2 (CK2), a constitutively active serine/threonine kinase that phosphorylates numerous metabolic, growth, and survival substrates, providing additional mechanistic depth to MOTS-c's effects on skeletal muscle gene expression and metabolism [3]. The original Cell Metabolism paper documented that subcutaneous MOTS-c administration at 0.5 mg/kg/day to mice prevented age-dependent and high-fat-diet-induced insulin resistance, reduced diet-induced obesity, increased glucose tolerance, and shifted skeletal muscle gene expression toward an oxidative phenotype. Plasma glucose, insulin, and HOMA-IR all improved significantly, and the peptide had no adverse effects on body weight in normal-chow controls. Subsequent studies extended these findings to models of metabolic syndrome, ovariectomy-induced bone loss (where MOTS-c preserved bone mineral density), and cisplatin-induced acute kidney injury. In humans, plasma MOTS-c can be detected by mass spectrometry and ELISA, with concentrations in the low nanomolar range that decline by approximately 50 percent across the adult lifespan. Higher circulating MOTS-c is associated with greater muscle MOTS-c expression, slow-twitch fiber predominance, and better insulin sensitivity in healthy aging men. CohBar developed a MOTS-c analog called CB4211 that entered Phase Ib clinical trials for non-alcoholic steatohepatitis and obesity in 2020–2022; the program was discontinued before pivotal trials due to commercial considerations rather than safety failure. Research subcutaneous self-administration of MOTS-c typically uses 5–10 mg two or three times per week, although no validated human dose or pharmacokinetic data are publicly available for these protocols [4].
Clinical Trial Efficacy Highlights
- starLee and colleagues reported in Cell Metabolism (2015) that MOTS-c administration at 0.5 mg/kg/day subcutaneously to mice prevented age-dependent and high-fat-diet-induced insulin resistance and obesity, increased glucose utilization and fatty acid oxidation, activated AMPK, and improved HOMA-IR insulin resistance index, establishing the foundational metabolic profile of mitochondrial-derived peptides [1].
- starReynolds and colleagues (Nature Communications 2021) demonstrated that MOTS-c is induced in human skeletal muscle by exercise and in circulation, that intermittent late-life MOTS-c administration to aged mice increased running capacity, grip strength, and lifespan markers, and that MOTS-c-treated muscle showed adaptation toward an exercise-trained phenotype [2].
- starKim and colleagues (Physiological Reports 2019) reported in a small human cohort that healthy aging men exhibited paradoxically higher skeletal muscle MOTS-c expression than younger men, with correlations to slow-twitch fiber composition and insulin sensitivity, providing observational human data linking endogenous MOTS-c to metabolic health across the lifespan [4].
- starHashimoto and colleagues (Cell Reports 2018) demonstrated that MOTS-c translocates from mitochondria to the nucleus under metabolic stress, binding antioxidant response elements and modulating nuclear gene expression, mechanistically expanding the role of mitochondrial-derived peptides beyond cytosolic signaling [5].
- starPre-clinical studies in ovariectomized mice demonstrated that MOTS-c administration preserves bone mineral density and reduces osteoclast activity, suggesting potential applications in age-related bone loss and osteoporosis [4].
- starAn investigational MOTS-c analog (CB4211) developed by CohBar entered Phase Ib clinical trials for non-alcoholic steatohepatitis and obesity in 2020–2022, demonstrating safety and tolerability in initial human exposure; the development program was discontinued for commercial reasons rather than safety concerns [3].
- starMechanistic studies show that MOTS-c directly binds and activates casein kinase 2 (CK2), providing an additional pathway by which the peptide regulates skeletal muscle metabolism, gene expression, and adaptation to exercise; CK2 activity is increased in muscle by both exercise and exogenous MOTS-c [3].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningNo formal human safety data have been published for off-label research subcutaneous MOTS-c administration; the CB4211 Phase Ib trials of a MOTS-c analog reported generally favorable tolerability but did not characterize chronic high-dose exposure.
- warningInjection-site reactions including erythema, mild swelling, bruising, and transient itching are the most commonly reported observations in self-administered MOTS-c protocols, similar to other small subcutaneous peptides.
- warningTheoretical risks of AMPK activation and metabolic acceleration include hypoglycemia, particularly when combined with insulin, sulfonylureas, or other glucose-lowering agents, although clinically significant hypoglycemia has not been reported with standard MOTS-c dosing.
- warningMild gastrointestinal effects, transient fatigue, headache, and flushing have been reported anecdotally in research protocols, although attribution to MOTS-c specifically rather than placebo or other concurrent interventions is difficult.
- warningLong-term safety of chronic MOTS-c administration, including potential effects on glucose homeostasis, cardiovascular function, and cancer biology, has not been characterized in humans.
- warningMOTS-c should be avoided in pregnancy, lactation, and in individuals with active malignancy until controlled human safety data are available; the broad metabolic and gene-expression effects of MDPs warrant caution.
- warningSterile injection technique is essential because self-administered MOTS-c is typically supplied as research-grade lyophilized peptide of variable purity, with risks of cutaneous infection and bloodborne pathogen exposure with non-sterile handling.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical MOTS-c dosage?expand_more
Research subcutaneous protocols typically use 5–10 mg two or three times per week, often in cycles of four to twelve weeks. No validated human dose has been established. Animal studies used 0.5 mg/kg/day; allometric scaling to humans would suggest similar weekly doses but is unreliable.
How is MOTS-c administered?expand_more
MOTS-c is administered by small-volume subcutaneous injection, usually into the abdomen, using an insulin syringe after reconstitution of lyophilized peptide with bacteriostatic water. No oral or transdermal route is bioavailable. Intravenous use has been employed in some research animal models.
Can MOTS-c be combined with other compounds?expand_more
MOTS-c is sometimes stacked with semaglutide, tirzepatide, or AMPK activators in metabolic protocols, although combined safety has not been studied. Combination with insulin or sulfonylureas increases hypoglycemia risk. Avoid stacking with other unapproved exercise mimetics without supervision.
What are the side effects of MOTS-c?expand_more
Reported observations are limited to mild injection-site reactions, occasional fatigue, headache, and gastrointestinal upset. Hypoglycemia risk increases when combined with glucose-lowering drugs. Long-term safety is uncharacterized in humans; no formal Phase II/III human safety database exists.
Is MOTS-c FDA approved?expand_more
No. MOTS-c is not FDA approved for any indication. A MOTS-c analog (CB4211) developed by CohBar entered Phase Ib clinical trials for non-alcoholic steatohepatitis but was discontinued for commercial reasons. MOTS-c is sold as a research peptide and used off-label without regulatory approval.
Academic References & Study Citations
Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. View Scientific Paper →
Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. View Scientific Paper →
Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524.e7. View Scientific Paper →
Kim SJ, Devgan A, Miller B, et al. Circulating levels of MOTS-c, a mitochondrial-derived peptide, in healthy aging men. Physiol Rep. 2019;7(12):e14171. View Scientific Paper →
Lu H, Wei M, Zhai Y, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med (Berl). 2019;97(4):473-485. View Scientific Paper →
Yin Y, Pan Y, He J, et al. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacol Res. 2022;175:105987. View Scientific Paper →
Du C, Zhang C, Wu W, et al. Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatr Diabetes. 2018;19(1):28-33. View Scientific Paper →
D'Souza RF, Woodhead JST, Hedges CP, et al. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY). 2020;12(6):5244-5258. View Scientific Paper →
Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC. MOTS-c, the most recent mitochondrial-derived peptide in human aging and age-related diseases. Int J Mol Sci. 2022;23(19):11991. View Scientific Paper →